Cargando…
Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma
BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507320/ https://www.ncbi.nlm.nih.gov/pubmed/34641921 http://dx.doi.org/10.1186/s13045-021-01180-5 |
_version_ | 1784581830811320320 |
---|---|
author | Liang, Lei Li, Chao Wang, Ming-Da Wang, Hong Zhou, Ya-Hao Zeng, Yong-Yi Zhang, Wan-Guang Chen, Ting-Hao Wang, Nan-Ya Li, Jie Zhang, Yao-Ming Wang, Yu Gu, Wei-Min Xing, Hao Diao, Yong-Kang Lau, Wan Yee Zhang, Cheng-Wu Pawlik, Timothy M. Shen, Feng Huang, Dong-Sheng Yang, Tian |
author_facet | Liang, Lei Li, Chao Wang, Ming-Da Wang, Hong Zhou, Ya-Hao Zeng, Yong-Yi Zhang, Wan-Guang Chen, Ting-Hao Wang, Nan-Ya Li, Jie Zhang, Yao-Ming Wang, Yu Gu, Wei-Min Xing, Hao Diao, Yong-Kang Lau, Wan Yee Zhang, Cheng-Wu Pawlik, Timothy M. Shen, Feng Huang, Dong-Sheng Yang, Tian |
author_sort | Liang, Lei |
collection | PubMed |
description | BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC. METHODS: From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE. RESULTS: A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE. CONCLUSIONS: Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01180-5. |
format | Online Article Text |
id | pubmed-8507320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-85073202021-10-20 Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma Liang, Lei Li, Chao Wang, Ming-Da Wang, Hong Zhou, Ya-Hao Zeng, Yong-Yi Zhang, Wan-Guang Chen, Ting-Hao Wang, Nan-Ya Li, Jie Zhang, Yao-Ming Wang, Yu Gu, Wei-Min Xing, Hao Diao, Yong-Kang Lau, Wan Yee Zhang, Cheng-Wu Pawlik, Timothy M. Shen, Feng Huang, Dong-Sheng Yang, Tian J Hematol Oncol Letter to the Editor BACKGROUND AND AIMS: Although adjuvant transcatheter arterial chemoembolization (TACE) for resected hepatocellular carcinoma (HCC) may improve survival for some patients, identifying which patients can benefit remains challenging. The present study aimed to construct a survival prediction calculator for individualized estimating the net survival benefit of adjuvant TACE for patients with resected HCC. METHODS: From a multicenter database, consecutive patients undergoing curative resection for HCC were enrolled and divided into the developing and validation cohorts. Using the independent survival predictors in the developing cohort, two nomogram models were constructed for patients with and without adjuvant TACE, respectively, which predictive performance was validated internally and externally by measuring concordance index (C-index) and calibration. The difference between two estimates of the prediction models was the expected survival benefit of adjuvant TACE. RESULTS: A total of 2514 patients met the inclusion criteria for the study. The nomogram prediction models for patients with and without adjuvant TACE were, respectively, built by incorporating the same eight independent survival predictors, including portal hypertension, Child–Pugh score, alpha-fetoprotein level, tumor size and number, macrovascular and microvascular invasion, and resection margin. These two prediction models demonstrated good calibration and discrimination, with all the C-indexes of greater than 0.75 in the developing and validation cohorts. A browser-based calculator was generated for individualized estimating the net survival benefit of adjuvant TACE. CONCLUSIONS: Based on large-scale real-world data, an easy-to-use online calculator can be adopted as a decision aid to predict which patients with resected HCC can benefit from adjuvant TACE. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13045-021-01180-5. BioMed Central 2021-10-12 /pmc/articles/PMC8507320/ /pubmed/34641921 http://dx.doi.org/10.1186/s13045-021-01180-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Letter to the Editor Liang, Lei Li, Chao Wang, Ming-Da Wang, Hong Zhou, Ya-Hao Zeng, Yong-Yi Zhang, Wan-Guang Chen, Ting-Hao Wang, Nan-Ya Li, Jie Zhang, Yao-Ming Wang, Yu Gu, Wei-Min Xing, Hao Diao, Yong-Kang Lau, Wan Yee Zhang, Cheng-Wu Pawlik, Timothy M. Shen, Feng Huang, Dong-Sheng Yang, Tian Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title_full | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title_fullStr | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title_full_unstemmed | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title_short | Development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
title_sort | development and validation of a novel online calculator for estimating survival benefit of adjuvant transcatheter arterial chemoembolization in patients undergoing surgery for hepatocellular carcinoma |
topic | Letter to the Editor |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8507320/ https://www.ncbi.nlm.nih.gov/pubmed/34641921 http://dx.doi.org/10.1186/s13045-021-01180-5 |
work_keys_str_mv | AT lianglei developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT lichao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT wangmingda developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT wanghong developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT zhouyahao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT zengyongyi developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT zhangwanguang developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT chentinghao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT wangnanya developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT lijie developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT zhangyaoming developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT wangyu developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT guweimin developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT xinghao developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT diaoyongkang developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT lauwanyee developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT zhangchengwu developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT pawliktimothym developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT shenfeng developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT huangdongsheng developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma AT yangtian developmentandvalidationofanovelonlinecalculatorforestimatingsurvivalbenefitofadjuvanttranscatheterarterialchemoembolizationinpatientsundergoingsurgeryforhepatocellularcarcinoma |